NPS Pharma's hypoparathyroidism Treatment 'Natpara' Wins FDA Approval

FDA Approves Natpara® (parathyroid hormone) for Injection as an Adjunct to Calcium and Vitamin D to Control Hypocalcemia in Patients with Hypoparathyroidism.Natpara, a bioengineered replica of human PTH, is expected to be available in the second quarter of 2015.

Source:
www.businesswire.com/news/home/20150123005803/en/FDA-Approves-Natpara%C2%AE-parathyroid-hormone-Injection-Adjunct#.VMNH3fmUc8o